Annovis Bio Announces Filing of Patent Covering the Administration of Buntanetap and Its Analogues for the Treatment of Mental Illnesses

By WebmasterFebruary 1, 2023November 1st, 2024No Comments

Annovis Bio Announces Filing of Patent Covering the Administration of Buntanetap and Its Analogues for the Treatment of Mental Illnesses

Previous PostServices for the UnderServed (S:US) Partners with Ride Health to Improve Transportation for Clients with Intellectual and Developmental Disabilities (I/DD)
Next PostiVIEW Therapeutics announces a successful pre-IND meeting with FDA and Received its Full Agreement on Development Plans for IVW-1001, a Novel Treatment for Dry Eye Disease